Full Generic Medicine Info
Dosage/Direction for Use

Male hypogonadism
Adult: 10-50 mg daily.

Metastatic breast carcinoma in postmenopausal women
Adult: 50-200 mg daily.
Men with breast cancer, known or suspected prostate cancer. Pregnancy.
Special Precautions
Patient with CV disease, benign prostatic hyperplasia, chronic lung disease; obesity. Renal and hepatic impairment. Lactation. Monitoring Parameters Monitor LFTs, lipid profile, haemoglobin and haematocrit (at 3-6 months and annually thereafter); urine, and serum Ca. Monitor serum glucose in diabetic patients; prostate specific antigen if clinically indicated. Assess for signs of virilisation in women. Perform radiologic examination of the wrist and hand for prepubertal patients every 6 months.
Adverse Reactions
Significant: Peliosis hepatis, hepatic neoplasms, hepatocellular carcinoma, cholestatic hepatitis, jaundice, MI, stroke, DVT, pulmonary embolism, polycythaemia, oligospermia, reduced ejaculatory volume, priapism, benign prostatic hypertrophy, sleep apnoea. Blood and lymphatic system disorders: Clotting factors suppression. Endocrine disorders: Hirsutism. Gastrointestinal disorders: Nausea, vomiting. Immune system disorders: Anaphylactic reactions. Investigations: Change in libido. Metabolism and nutrition disorders: Hypercholesterolaemia. Nervous system disorders: Headache, paraesthesia. Psychiatric disorders: Depression, anxiety. Reproductive system and breast disorders: Amenorrhoea, impotence, mastalgia, testicular atrophy. Skin and subcutaneous tissue disorders: Acne vulgaris, androgenetic alopecia.
Drug Interactions
Enhanced effect of anticoagulants and hypoglycaemic agent. Increased hepatotoxicity of ciclosporin. Increased plasma concentrations of oxyphenbutazone.
Lab Interference
May decrease thyroxine-binding globulin concentrations.
Methyltestosterone is a synthetic anabolic steroid hormone which promotes growth and development of male sex organs. It also aids in the maintenance of secondary sex characteristics in androgen-deficient men.
Absorption: Absorbed from the gastrointestinal tract.
Distribution: Plasma protein binding: 98% mainly to sex hormone-binding globulin.
Metabolism: Metabolised in the liver.
Excretion: Mainly via urine (approx 90%); faeces (approx 6%). Elimination half-life: 10-100 minutes.
Oral: Store between 15-30°C. Protect from light, moisture, and heat.
CIMS Class
Androgens & Related Synthetic Drugs / Cytotoxic Chemotherapy
ATC Classification
G03EK01 - methyltestosterone ; Belongs to the class of androgens and female sex hormones in combination.
G03BA02 - methyltestosterone ; Belongs to the class of 3-oxoandrosten (4) derivative androgens used in androgenic hormone preparations.
Disclaimer: This information is independently developed by CIMS based on methyltestosterone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in